Impacto de Hormona Somatostatina y Analogos Radiomarcados en Diagnostico de Tumores Malignos.7
27. Pinski J, Milovanovic TY, Hamaoui A et al. Biological activity and receptor binding characteristics to various human tumors of acetylated somatostatin receptors. Proc Soc Exp Biol Med 1992; 200: 49–56.
28. Smith-Jones PM, Bischof C, Leimer M, et al. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology 1999; 140: 5136 - 48.
29. Kaltsas GA, Mukherjee JJ & Grossman AB. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours. Annals of Oncology 2001; 12 (Suppl 2) S47–S50.
30. de Herder WW, Hofland LJ, van der Lely AJ et al. Peptide receptors in gut endocrine tumours. Bailliere’s Clinical Gastroenterology 1996; 10: 571–87.
31. Van EijK CHJ, Krenning EP, Bootsma A, Oei HY, Van Pel R, Lindemans J et al. Somatostatin -receptor scintigraphy in primary breast cancer. Lancet 1994; 12:640-3.
32. Brian F. Hutton. Tomografía por Emisión. Temas Avanzados. In: Heather E. Patterson y Brian F. Hutton, editors. Versión en Español: Margarita Núñez. Organización Internacional de Energía Atómica. Programa Asistido de Capacitación a Distancia para Tecnólogos en Medicina Nuclear. Módulo 9. Unidad 12 b.
33. Jarrit PH, Carson KJ, Hounsel AR et al. The rol of PET/CT scanning in radioteherapy planning. Br J Radiol 2006 Spec No 1: S27-35.
34. Tsukamoto E, Ochi S. PET/CT today: system and its impact on cancer diagnosis. Ann Nucl Med 2006; 20 : 255-67.
35. Schillaci O, Filippi L, Danieli R et al. Single-photon emision computed tomography/ computed tomography in abdominal diseases. Semin Nucl Med 2007; 37: 48-61
36. Schillaci O, Filippi L, Manni C et al. Single-photon emision computed tomography/ computed tomography in brain tumors. Semin Nucl Med 2007; 37: 34-47.
37. Pichler BJ, Judenhofer MS, Catana C et al. Performance test of an LSO-APD detector in a 7-T MRI scanner for simultaneaus PET/MRI. J Nucl Med 2006; 47: 639-47.
38. Seemann MD. Whole-body PET/MRI: The future in oncological imaging. Technol Cancer Res Treat 2005; 4: 577-82.
39. Yamamoto Y, Nishiyama Y, Monden T et al. Clinical usefulness of fusion of 131I SPECT and CT images in patients with differentiated thyroid carcinoma. J Nucl Med 2003; 44: 1905-10.
40. Schillaci O, Spanu A, Madeddu G. [99mTc]sestamibi and [99mTc]tetrofosmin in oncology: SPET and fusion imaging in lung cancer, malignant lymphomas and tumors. Q J Nucl Med Mol Imaging 2005; 49: 133-44.
41. Von Schulthess GK. Integrated modality imaging with PET-CT and SPECT-CT: CT issues. Eur Radiol 2005; 15 Suppl 4: D121-6.
42. Schillaci O. Single-photon emision computed tomography/ computed tomography in in lung cancer, malignant lymphoma. Semin Nucl Med 2006; 36: 275-85.
43. Thakur ML. Radiolabelled peptides: Now and the future. Nucl Med Commun 1995;16:724–32.
44. Fischman AJ, Babich JW, Strauss HW. A ticket to ride: Peptide radiopharmaceuticals. J Nucl Med 1993;34:2253–63.
45. Khawli LA, Kassis AI. Synthesis of 125I labeled N-succinimidyl p-iodobenzoate for use in radiolabelling antibodies. Nucl Med Biol 1989;16:727–33.
46. Zalutsky MR, Narula AS.A method for radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine. Appl Radiat Isot 1987;38:1051–5.
47. Hnatowich DJ. Recent developments in the radiolabeling of antibodies with iodine, indium, and technetium. Semin Nucl Med 1990;20:80–91.
48. Baker RJ, Diamanti CI, Goodwin DA et al. Technetium-99m complexes of EDTA analogs: Studies of the radiochemistry and biodistribution. Int J Nucl Med Biol 1981;8:159–69.
49. Liu S, Edwards DS. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev 1999; 99:2235–68.
50. Lin KS, Luu AN, Baidoo KE, Pili R, Carducci MA, Wagner HN, Jr. In vivo evaluation of a promising 99mTc-labeled bombesin analog for breast cancer imaging. In: Nicolini M, Mazzi U, editors. Technetium, rhenium, and other metals in chemistry and nuclear medicine 6. Padova: SGEditoriali; 2002. pp 363-7.
51. Guhlke S, Schaffland A, Zamora PO et al. 188Re- and 99mTc-MAG3 as prosthetic groups for labeling amines and peptides: Approaches with pre- and postconjugate labeling. Nucl Med Biol 1998;25:621–31.
52. Maina T, Nock B, Nikolopoulou A et al. [99mTc]Demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptorpositive tumours: Synthesis and preclinical results. Eur J Nucl Med 2002;29:742–53.
53. Decristoforo C, Mather SJ, Cholewinski W et al 99mTc-EDDA/HYNIC-TOC: A new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: First clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med 2000;27:1318–25.
54. Rhodes BA. Direct labeling of proteins with 99mTc. Nucl Med Biol 1991;18: 667–76.
55. Zamora PO, Rhodes BA. Imidazoles as well as thiolates in proteins bind technetium-99m. Bioconjug Chem 1992;3: 493–8.
56. Maecke HR, Hofmann M, Haberkorn U. 68Ga-labeled peptides in tumor imaging. J Nucl Med 2005;46:172S–8S.
57. Green MA, Welch MJ. Gallium radiopharmaceutical chemistry. Nucl Med Biol 1989;16:435–48.
58. Eisenwiener KP, Prata MIM, Buschmann I et al. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug Chem 2002; 13: 530–41.
59. Guhlke S, Wester HJ, Bruns C, Sto¨cklin G. (2-[18F]fluoropropionyl-(D)phe1)-octreotide, a potential radiopharmaceutical for quantitative somatostatin receptor imaging with PET: Synthesis, radiolabelling, in vitro validation, and biodistribution in mice. Nucl Med Biol 1994;21:819–25.
60. Wester H-J, Hamacher K, Sto¨cklin G. A comparative study of N.C.A. fluorine-18 labeling of proteins via acylation and photochemical conjugation. Nucl Med Biol 1996; 23: 365–72.
61. Vaidyanathan G, Binger DD, Zalutsky MR. Fluorine-18-labeled monoclonal antibody fragments: A potential approach for combining radioimmunoscintigraphy and positron emission tomography. J Nucl Med 1992;33:1535–41.
62. Hostetler ED, Edwards WB, Anderson CJ, Welch MJ. Synthesis of 4-[18F]fluorobenzoyl octreotide and biodistribution in tumor-bearing Lewis rats. J Label Compounds Radiopharm 1999;42:S720–S721.
63. Lewis JS, Welch MJ. Copper chemistry related to radiopharmaceutical production. In: Nicolini M, Mazzi U, editors. Technetium, rhenium, and other metals in chemistry and nuclear medicine 6. Padova:SGEditoriali; 2002. pp 23–33.
64. Krenning EP, Kwekkeboom DJ, Bakker Wh et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and 123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716–31.
65. Krenning EP, Bakker WH, Breeman WA. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989; 4: 242-4.